DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eisai - 1 Leqembi - 1 ” - 1 Eric Reiman - 1 Priya Singhal - 1 Biogen - 1 Michael Irizarry - 1 Alzheimer's - 1
Top related locs:
Handout Boston Los Angeles
Top related orgs:
REUTERS - 1 Rights - 1 Banner Alzheimer's Institute - 1 ARIA - 1 Thomson - 1

Search resuls for: "Julie Steenhuysen Deena Beasley"


3 mentions found


☆ Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi
  + stars: | 2023-10-25 | by ( Julie Steenhuysen Deena Beasley | Julie Steenhuysen | Deena Beasley | ) www.reuters.com   time to read: +4 min
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Acquire Licensing RightsBOSTON, Oct 25 (Reuters) - An injected version of Eisai (4523.T) and Biogen's (BIIB.O) Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion. Blood concentration levels of the drug were 11% higher with subcutaneous Leqembi than the IV version. Roll-out of IV Leqembi, which has an annual list price of $26,500, has been slow.
Persons: Eisai, Leqembi, ”, Eric Reiman, Priya Singhal, Biogen, Michael Irizarry, Alzheimer's, Julie Steenhuysen, Deena Beasley, Bill Berkrot, Leslie Adler Organizations: Reuters, REUTERS, Rights, Banner Alzheimer's Institute, ARIA, Thomson Locations: Handout, Boston, Los Angeles
☆ Lilly drug slows Alzheimer's progression by 35% in trial
  + stars: | 2023-05-03 | by ( Julie Steenhuysen Deena Beasley | Julie Steenhuysen | Deena Beasley | ) www.reuters.com   time to read: +4 min
The drug, donanemab, met all goals of the trial. "These are the strongest phase 3 data for an Alzheimer's treatment to date," said Maria Carrillo, chief science officer for the Alzheimer's Association. In the donanemab treatment group, Lilly said brain swelling, a known side effect of drugs of this type, occurred in 24% of the participants, with 6.1% experiencing symptoms. In the Leqembi Phase 3 trial, the drug was associated with brain swelling in nearly 13% of its study participants. It also said 47% of donanemab patients in the 18-month trial had no disease progression at 12 months, compared with 29% of the placebo group.
☆ New COVID model predicts over 1 million deaths in China through 2023
  + stars: | 2022-12-17 | by ( Julie Steenhuysen Deena Beasley | Julie Steenhuysen | Deena Beasley | ) www.reuters.com   time to read: +4 min
According to the group's projections, cases in China would peak around April 1, when deaths would reach 322,000. About a third of China's population will have been infected by then, IHME Director Christopher Murray said. China's national health authority has not reported any official COVID deaths since the lifting of COVID restrictions. Based on China's population of 1.41 billion, and without measures such as a mass vaccination booster campaign, that amounts to 964,400 deaths. China's National Health Commission said on Friday it was ramping up vaccinations and building stocks of ventilators and essential drugs.
0 next >>
Total: 3